Comparative Pharmacology
Head-to-head clinical analysis: CLOMID versus SOLTAMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOMID versus SOLTAMOX.
CLOMID vs SOLTAMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of estrogen receptors (ER) in hypothalamus and pituitary, leading to increased gonadotropin-releasing hormone (GnRH) and subsequent LH and FSH release, stimulating ovulation.
Selective estrogen receptor modulator (SERM). Binds to estrogen receptors, competitively inhibiting estrogen binding. In breast tissue, acts as an antagonist; in bone and cardiovascular system, acts as an agonist.
50 mg orally once daily for 5 days, starting on day 5 of the menstrual cycle. May increase to 100 mg daily if no response.
300 mg orally once daily for 5 days, starting on day 1 of menses.
None Documented
None Documented
Terminal half-life is 5–7 days for zuclomiphene (active isomer), with prolonged elimination due to enterohepatic recirculation.
24-36 hours in adults; prolonged in renal impairment (up to 96 hours in ESRD). Steady-state reached in ~5 days.
Primarily hepatic metabolism; metabolites excreted in feces (42%) and urine (8% unchanged).
Primarily renal (80-90% as unchanged drug); biliary/fecal excretion accounts for 10-20%.
Category C
Category C
Selective Estrogen Receptor Modulator
Selective Estrogen Receptor Modulator